top of page

Example predictive testing template for reporting a positive CHEK2 or ATM germline pathogenic/likely pathogenic variant

Approved: May 2022

Example predictive testing template for reporting a positive CHEK2 or ATM germline pathogenic/likely pathogenic variant

Approved: May 2022

Example predictive testing template for reporting a BRCA or PALB2 germline pathogenic/likely pathogenic variant (reduced penetrance)

Approved: May 2022

​

Example predictive testing template for reporting a positive BRCA1 or PALB2 germline pathogenic/likely pathogenic variant

Approved: May 2022

Previous version: June 2021

Example predictive testing template for reporting a positive BRCA2 germline pathogenic/likely pathogenic variant

Approved: May 2022

Previous version: June 2021

Example predictive testing template for reporting a positive BRCA or PALB2 germline pathogenic/likely pathogenic variant

Approved: May 2022

Previous version (BRCA only): June 2021

PRED Report Template: BRCA/PALB2 Positive - Reduced Penetrance

Example predictive testing template for reporting a positive BRCA or PALB2 germline pathogenic/likely pathogenic variant (reduced penetrance)

Approved: May 2022

Example predictive testing template for reporting a negative variant for the R208 germline panel

Approved: May 2022

Previous version: June 2021

Example diagnostic testing template for reporting a CHEK2 or ATM germline pathogenic/likely pathogenic variant.

Approved: May 2022

Example diagnostic testing template for reporting ATM c.7271T>G p.(Val2424Gly) 

Approved: May 2022

Example diagnostic testing template for reporting a BRCA or PALB2 germline pathogenic/likely pathogenic variant.

Approved: May 2022

Previous version (BRCA only): June 2021

Example diagnostic testing template for reporting a reduced penetrance BRCA or PALB2 germline pathogenic/likely pathogenic variant.

Approved: May 2022

​

Example diagnostic testing template for reporting a BRCA or PALB2 germline pathogenic/likely pathogenic variant.

Approved: May 2022

​

Example diagnostic testing template for reporting where a variant of uncertain significance (VUS) is identified in the R208 panel (including CHEK2 and ATM)

Approved: May 2022

Previous version (BRCA only): June 2021

Example diagnostic testing template for reporting no germline pathogenic/likely pathogenic variants identified in the R208 panel (including CHEK2 and ATM)

Approved: May 2022

Previous version (BRCA only): June 2021

Example template for reporting a germline pathogenic/likely pathogenic variant in the Ovarian Cancer R207 diagnostic panel.

Approved: June 2022

Previous version: June 2021

Example template for reporting a germline variant of uncertain significance in the Ovarian Cancer R207 diagnostic panel.

Approved: June 2022

​

Example template for reporting no germline pathogenic/likely pathogenic variants in the Ovarian Cancer R207 diagnostic panel.

Approved: June 2022

​

Example template for reporting a germline pathogenic/likely pathogenic variant in the Prostate Cancer R430 diagnostic panel.

Approved: September 2023

​

Example template for reporting a germline variant of uncertain significance in the Prostate Cancer R430 diagnostic panel.

Approved: September 2023

​

Example template for reporting no germline pathogenic/likely pathogenic variants in the Prostate Cancer R430 diagnostic panel.

Approved: September 2023

Example diagnostic testing template for reporting a reduced penetrance germline pathogenic/likely pathogenic variant in the Prostate Cancer R430 diagnostic panel.

Approved: September 2023

​

Example Report Templates

External Resources

ACGS

The Association for Clinical Genomic Science brings together scientists working within genetics into one professional association.

JMG Paper

Cancer Variant Interpretation Group UK (CanVIG-UK): an exemplar national subspecialty multidisciplinary network.

 

Journal of Medical Genetics

Published: 13 March 2020.

UKCGG

The UK Cancer Genetics Group.

​

A multidisciplinary organisation for UK clinicians, counsellors & scientists interested in cancer susceptibility genetics.

ACMG

The American College of Medical Genetics variant interpretation framework can be found on their website. 

bottom of page